Is GoodRx Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, GoodRx Holdings, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 38, a Price to Book Value of 2.23, and an EV to EBITDA of 9.64, which suggest that the stock is priced higher relative to its earnings and book value compared to its peers.
In comparison to its peers, GoodRx's P/E ratio of 31.76 is significantly better than PropertyGuru Group Ltd., which has a P/E of -132.05, indicating that GoodRx is relatively more stable in terms of earnings. However, the overall industry context suggests that GoodRx is not a strong performer, especially when considering its recent stock performance; it has underperformed the S&P 500 across multiple time frames, including a staggering -44.33% return over the past year compared to the S&P 500's 14.08%.